Nuvalent, Inc. (NUVL)
| Market Cap | 8.01B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -425.38M |
| Shares Out | 78.62M |
| EPS (ttm) | -5.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 277,590 |
| Open | 104.49 |
| Previous Close | 104.04 |
| Day's Range | 101.25 - 106.10 |
| 52-Week Range | 63.56 - 113.02 |
| Beta | 1.31 |
| Analysts | Strong Buy |
| Price Target | 134.75 (+32.24%) |
| Earnings Date | May 8, 2026 |
About NUVL
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for NUVL stock is "Strong Buy." The 12-month stock price target is $134.75, which is an increase of 32.24% from the latest price.
News
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Nuvalen...
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
Zidesamtinib demonstrated meaningful clinical activity in subset of TKI pre-treated ROS1-positive NSCLC patients from ARROS-1 trial previously treated with repotrectinib or taletrectinib, including in...
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial CAMBRIDGE, Mass., April 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a ...
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
Nuvalent Transcript: Leerink Global Healthcare Conference 2026
Significant progress was highlighted across ROS1 and ALK programs, with rapid trial enrollment, strong clinical data showing high response rates and durability, and regulatory milestones positioning both drugs for potential approval and commercial launch. Plans include global commercialization and further pipeline expansion.
Nuvalent Transcript: TD Cowen 46th Annual Health Care Conference
Multiple oncology programs are advancing toward key regulatory milestones in 2024, with strong physician and patient advocacy support driving rapid trial enrollment. Lead assets target significant market opportunities in ALK and ROS1 lung cancer, with commercial readiness and global registration strategies in place.
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review; PDUFA target action date of Septe...
Nuvalent Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The company is advancing global commercialization of differentiated ROS1 and ALK inhibitors, with US launches expected this year and ex-US expansion underway. Strong clinical data, robust financials, and a growing pipeline—including HER2 and a new candidate—support a vision for sustainable global growth.
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase t...
Nuvalent Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted progress on targeted NSCLC therapies, with pivotal data for zidesamtinib and NVL-655 supporting upcoming FDA submissions and potential approvals. Strong clinical results, commercial readiness, and a robust pipeline position the company for sustainable growth and global expansion.
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI p...
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
Nuvalent Appoints Ron Squarer to Board of Directors
CAMBRIDGE, Mass. , Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
Nuvalent Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing two late-stage oncology programs, NVL-655 for ALK and zidesamtinib for ROS1, both showing strong durability and safety profiles. Rapid trial enrollment and patient advocacy partnerships support commercial readiness, with first approvals targeted for 2026.
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 26, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass. , Nov. 19, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL)...
Nuvalent Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , Nov. 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
Nuvalent Announces Public Offering of Common Stock
CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer
Nuvalent, Inc. (NASDAQ: NUVL) on Monday reported topline results from its ALKOVE-1 Phase 1/2 trial.
Nuvalent Transcript: Study Update
Neladalkib showed durable responses in heavily pretreated ALK-positive NSCLC, including Lorlatinib-experienced patients, with a favorable safety profile and strong CNS activity. The drug demonstrated high ORR and DOR in both pretreated and TKI-naive cohorts, supporting its potential as a new standard of care.
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectively In the subs...
Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib
Company to host webcast and conference call on November 17, 2025 at 8:00am ET CAMBRIDGE, Mass. , Nov. 14, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company...
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session CAMBRIDGE, Mass. , Nov. 4, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stag...
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC On track to report topline pivotal data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC ...